ABSTRACT DNA methylation at Hpall (CmCGG) sites inhibits expression of a human proenkephalin-CAT fusion gene when it is transiently expressed in CV-1 cells or stably expressed in C6-glioma cells. The inhibitory effects of Hpall methylation have been mapped to a site within the human proenkephalin promoter located at position -72 relative to the start site of transcription. This region spans a cAMP and phorbol ester inducible enhancer and methylation at this position inhibits both basal transcription and transcription induced by either cAMP or TPA. The Hpall site is located within an element which binds the transcription factor AP-2. In vitro methylation at this Hpall site inhibits the binding of AP-2. These results suggest that CpG methylation inhibits proenkephalin gene expression by directly interfering with the binding of a positively acting transcription factor previously shown to be essential for maximal basal, cAMP, and TPA inducible transcription.
INTRODUCTION
Transcriptional control of gene expression involves the interaction of a large number of cellular trans-acting factors with cis-acting DNA elements to promote transcription (1, 2) . Temporal and tissue-specific regulation of gene expression may depend upon the activity of various DNA binding proteins. The activity of these proteins may in turn be determined by a variety of cellular signals, protein/protein interactions, as well as the structure and accessibility of the gene in its local chromatin environment (3) (4) (5) (6) (7) . Modification of DNA structure by DNA methylation may play an important role in controlling DNA/protein interactions and result in the activation or repression of gene expression. The comparison of DNA methylation patterns before and after induction of gene expression, or between expressing and nonexpressing cell types, correlates the loss of methylation at specific CpG sites within promoter regions with gene expression (3) (4) (5) (6) (7) (8) . In general, an inverse correlation between gene expression and DNA methylation at CpG dinucleotides has been established for a variety of vertebrate and viral genes (4, 5) . In addition, in vitro cytosine methylation at specific CpG residues within a variety of cellular and viral genes, followed by reintroduction of the methylated genes into tissue culture cells, dramatically inhibits gene expression (9, (13) (14) (15) (16) (17) (18) (19) (20) . Although the mechanism of this effect has not been determined, recent evidence supports two different models. DNA methylation at CpG dinucleotides located within the binding sites of positive acting transcription factors may alter protein/DNA interactions (3, (35) (36) (37) . Alternatively, methylation may indirectly effect transcription by altering chromatin structure (34) .
The human proenkephalin promoter region contains 10 times the number of CpG dinucleotides expected at random and some CpG sites have been shown by analysis of genomic DNA to be methylated in a tissue specific fashion (21) . Recently, a cAMP and phorbol ester inducible enhancer has been localized within the promoter region (22) . A detailed point mutation analysis of the inducible enhancer region has resolved the enhancer into multiple DNA elements located within a 50 base pair region of DNA (-64 to -114) upstream of the transcription initiation site (23) . Furthermore, each of these elements act synergistically to activate transcription in the presence of cAMP or phorbol esters. Four different DNA binding proteins have been shown to interact with these elements in vitro (23) . One of these proteins, AP-2, which also interacts with the SV40 (24) and metallothionein (25) enhancers, binds to a site within the proenkephalin enhancer located by DNase I footprinting between -85 and -65 base pairs upstream of the start site of transcription (23, 24, 27 Figure 1 . a) Schemiatic diagram of the human proenkephalin and mouse POMC/CAT fusion plasmids. Construction of these plasmids has been described previously (22) . Hpall methylation and incorporation of 5-methylcytosine inhibits the binding of AP-2 To examine the mechanism of action of Hpall methylation we next tested whether Hpall methylation affected the binding of proteins to the region spanning the HpaII site located 72 base pairs upstream of the start site of transcription. DNase I footprinting experiments using crude HeLa cell nuclear extracts (data not shown) indicated that the binding of a nuclear factor to the -85 to -65 region of the enhancer was inhibited by HpaII methylation. Previously, we have demonstrated that this region is protected by the transcription factor AP-2 (23, 24, 27) . We next tested whether the binding of affinity purified AP-2 was inhibited by Hpall methylation. As shown in Figure 3a and 3b the binding of affinity purified AP-2 to the -85 to -65 region of the proenkephalin enhancer is inhibited by Hpall methylation but not by Hha .:
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. promoters (36) . In addition, binding of as yet unidentified proteins to the tyrosine aminotransferase gene (3) and binding of ATF/CREB-like proteins to the CRE (37) are inhibited by CpG methylation. These results suggest that the DNA binding affinity of certain transcription factors may be regulated by CpG DNA methylation.
The results presented here demonstrate that methylation at a single Hpall site within the proenkephalin promoter inhibits both basal and cAMP inducible transcription. This HpaII site lies within a region of DNA previously shown to act as a cAMP inducible enhancer which consists of at least three tightly-spaced adjacent DNA elements; ENKCRE-1, ENKCRE-2, and an AP-2 binding element (Figure 4) (23) . Each element is essential for maximal basal, cAMP, and TPA inducible transcription (23, 26) and each functions synergistically with the other elements. For example, the AP-2 binding element or the ENKCRE-l element which themselves are unable to promote basal or inducible transcription will greatly augment cAMP or TPA inducible transcription in the presence of a functional ENKCRE-2 element (23, 26) . Mutations which inactivate the AP-2 site yet leave the ENKCRE-1 and ENKCRE-2 elements intact result in a 4 to 6 fold reduction in cAMP and TPA inducible transcription and a several fold reduction in basal transcription (26) . The effects of inactivating the AP-2 element by mutation are very similar to the effects of Hpall methylation within the element. Hence, both mutation and DNA methylation within the AP-2 binding site produce functionally similar inhibitory effects on the in vivo activity of the human proenkephalin cAMP and phorbol ester inducible enhancer.
In vitro binding of the transcription factor, AP-2, to the proenkephalin enhancer is inhibited by CpG methylation at the HpaII site or by incorporation of 5-methylcytosine within the AP-2 site. Together these results suggest that HpaH methylation acts to inhibit proenkephalin gene expression in vivo by reducing the affinity of a positively acting transcription factor, AP-2, with its DNA recognition site located within the cAMP and TPA inducible enhancer.
The role of CpG methylation in the developmental and tissuespecific regulation of human proenkephalin gene expression has yet to be determined. Competition between the binding of transcription factors to CpG containing recognition sites and methylation dependent inhibition of factor binding is an attractive mechanism to produce stable alterations in gene expression both during development, and in the mature organism. Displacement of transcription factor binding by tissue-specific methylation at sites spanning the inducible enhancer could result in either positive or negative effects on transcription depending on the activity of the displaced factor. Furthermore, tissue-specific differences in DNA methylation could serve to regulate factor interactions and hence the mode of transcriptional regulation in cells expressing the same set of transcription factors. 
